These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 3087873)

  • 1. Competition between valproate & phenytoin for plasma protein binding.
    Jaffery NF; Ahmad SN; Jailkhani BL
    Indian J Med Res; 1986 Apr; 83():426-8. PubMed ID: 3087873
    [No Abstract]   [Full Text] [Related]  

  • 2. Binding of drugs to human serum albumin. XIV. The theoretical basis for the interaction between phenytoin and valproate.
    Kober A; Olsson Y; Sjöholm I
    Mol Pharmacol; 1980 Sep; 18(2):237-42. PubMed ID: 6775182
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of valproate on free plasma phenytoin concentrations.
    Tsanaclis LM; Allen J; Perucca E; Routledge PA; Richens A
    Br J Clin Pharmacol; 1984 Jul; 18(1):17-20. PubMed ID: 6430316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valproic acid: in vitro plasma protein binding and interaction with phenytoin.
    Cramer JA; Mattson RH
    Ther Drug Monit; 1979; 1(1):105-16. PubMed ID: 121944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein binding of digitoxin, valproate and phenytoin in sera from diabetics.
    Doucet J; Fresel J; Hue G; Moore N
    Eur J Clin Pharmacol; 1993; 45(6):577-9. PubMed ID: 8157046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum protein binding of diphenylhydantoin in man. II. Interaction with sodium valproate in epileptic patients.
    Gatti G; Lecchini S; Frigo GM; Visintini D; Calzetti S; Lombardi M; Cattaino G
    Farmaco Prat; 1979 Jan; 34(1):46-8. PubMed ID: 378689
    [No Abstract]   [Full Text] [Related]  

  • 7. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients.
    Joerger M; Huitema AD; Boogerd W; van der Sande JJ; Schellens JH; Beijnen JH
    Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):133-40. PubMed ID: 16918714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unbound phenytoin plasma concentrations in patients comedicated with sodium valproate--the predictive value of plasma albumin concentration.
    Johnson GJ; Kilpatrick CJ; Bury RW; Fullinfaw RO; Moulds RF
    Br J Clin Pharmacol; 1989 Jun; 27(6):843-9. PubMed ID: 2503019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variable in vivo binding of valproic acid in epilepsy patients being medicated with other anticonvulsants.
    Haidukewych D; Rodin EA
    Clin Chem; 1980 Oct; 26(11):1634-5. PubMed ID: 6774840
    [No Abstract]   [Full Text] [Related]  

  • 10. Valproate and palmitate binding to human serum albumin: an hypothesis on obesity.
    Brodersen R; Jørgensen N; Vorum H; Krukow N
    Mol Pharmacol; 1990 May; 37(5):704-9. PubMed ID: 2111005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of fosphenytoin, phosphate ester pro drug of phenytoin, to human serum proteins and competitive binding with carbamazepine, diazepam, phenobarbital, phenylbutazone, phenytoin, valproic acid or warfarin.
    Lai CM; Moore P; Quon CY
    Res Commun Mol Pathol Pharmacol; 1995 Apr; 88(1):51-62. PubMed ID: 7620838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma protein binding interaction between phenytoin and valproic acid in vitro.
    Monks A; Boobis S; Wadsworth J; Richens A
    Br J Clin Pharmacol; 1978 Dec; 6(6):487-92. PubMed ID: 365209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased plasma protein binding of phenytoin in patients on valproic acid.
    Dahlqvist R; Borgå O; Rane A; Walsh Z; Sjöqvist F
    Br J Clin Pharmacol; 1979 Dec; 8(6):547-52. PubMed ID: 391256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of sodium valproate, phenytoin and carbamazepine and seizure control in epilepsy.
    Goggin T; Casey C; Callaghan N
    Ir Med J; 1986 Jun; 79(6):150-6. PubMed ID: 3089966
    [No Abstract]   [Full Text] [Related]  

  • 15. Valproic acid in epilepsy: clinical and pharmacological effects.
    Mattson RH; Cramer JA; Williamson PD; Novelly RA
    Ann Neurol; 1978 Jan; 3(1):20-5. PubMed ID: 350128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum protein binding of phenytoin and valproic acid in insulin-dependent diabetes mellitus.
    Gatti G; Crema F; Attardo-Parrinello G; Fratino P; Aguzzi F; Perucca E
    Ther Drug Monit; 1987 Dec; 9(4):389-91. PubMed ID: 3122377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictability of unbound antiepileptic drug concentrations in children treated with valproic acid and phenytoin.
    Miles MV; Snead OC; Thorn MD
    Clin Pharm; 1988 Sep; 7(9):688-93. PubMed ID: 3149223
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy.
    Rastogi P; Mehrotra TN; Agarwala RK; Singh VS
    J Assoc Physicians India; 1991 Aug; 39(8):606-8. PubMed ID: 1814875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma protein binding of phenytoin in health and disease: relevance to therapeutic drug monitoring.
    Perucca E
    Ther Drug Monit; 1980; 2(4):331-44. PubMed ID: 7013166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum concentrations and enzyme induction in epileptic children treated with phenytoin and valproate.
    de Wolff FA; Peters AC; van Kempen GM
    Neuropediatrics; 1982 Feb; 13(1):10-3. PubMed ID: 6123089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.